ClinicalTrials.gg
Not yet recruitingNCT07044986Updated Jul 1, 2025

Ultrasonographic Evaluation of the Ulnar Nerve in Individuals With and Without Generalized Joint Hypermobility

An observational study in Hypermobility, Joint, sponsored by Beylikduzu State Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Beylikduzu State Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
60
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This study will include 30 individuals diagnosed with Generalized Joint Hypermobility (GJH) based on the Beighton score and 30 healthy controls without GJH. Participants will undergo Tinel's test and the flexion-compression test. The presence of ulnar nerve-related symptoms such as pain and numbness will be recorded. Ultrasonographic evaluation of the ulnar nerve will be performed at the level of the medial epicondyle, as well as 2 cm proximal and distal to it. Cross-sectional area and diameter of the ulnar nerve will be measured at each site, repeated three times, and the average will be used. Additionally, ulnar nerve mobility during elbow flexion and extension will be assessed. The nerve will be classified as stable if it remains within the cubital tunnel, subluxated if it moves to the level of the epicondyle, and dislocated if it shifts anterior to the medial epicondyle.

02

Conditions studied

  • Hypermobility, Joint

Browse trials for

03

In context

Joint Instability

115 studies on the registry are indexed under Joint Instability; 21 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 54 observational studies indexed under Joint Instability.

Browse Joint Instability studies →

Lead sponsor

Beylikduzu State Hospital is the lead sponsor of 23 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

hypermobility and healthy controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 40 years
  • A Beighton score of 4 or higher (indicative of Generalized Joint Hypermobility)
  • Willingness to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Being under 18 or over 40 years of age
  • History of surgery or fracture in the elbow region
  • Presence of active infection at the measurement site
  • Presence of congenital anomaly in the upper extremity
  • History of surgery involving neural structures in the upper extremity
  • Presence of
  • Pregnancy
  • Presence of cognitive or psychiatric disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • hypermobility

    patients with generalized joint hypermobility snyndrome

    Other: no intervention

  • Control group

    healthy control

    Other: no intervention

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Ulnar nerve cross-sectional area (CSA) at the medial epicondyle

    CSA measurement provides insight into nerve thickening, which may indicate entrapment or irritation.

    Time frame: 0 day

  2. Ulnar nerve cross-sectional area (CSA) at the 2 cm proximal of medial epicondyle

    CSA measurement provides insight into nerve thickening, which may indicate entrapment or irritation.

    Time frame: 0 day

  3. Ulnar nerve cross-sectional area (CSA) at the 2 cm distal of medial epicondyle

    CSA measurement provides insight into nerve thickening, which may indicate entrapment or irritation.

    Time frame: 0 day

  4. Ulnar nerve diameter

    Ulnar nerve diameter with ultrasonography

    Time frame: 0 day

  5. Ulnar nerve mobility classification during elbow flexion (stable/subluxated/dislocated)

    Dynamic USG evaluation allows visualization of nerve movement and instability during joint motion.

    Time frame: 0 day

Secondary outcomes

  1. Presence of ulnar nerve-related symptoms:

    Symptom inquiry helps correlate clinical complaints with sonographic findings.

    Time frame: 0 day

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2025; primary completion for Aug 2025, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2025
First posted
Jul 1, 2025
StartEst.
Jul 1, 2025
Primary completionEst.
Aug 1, 2025
CompletionEst.
Aug 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07044986
Lead sponsor
Beylikduzu State Hospital
Responsible party
Busra Sirin (Principle Investigator, Beylikduzu State Hospital) — Principal investigator
First posted
Jul 1, 2025
Start date
Jul 1, 2025 (estimated)
Primary completion
Aug 1, 2025 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
Jul 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion